RECRUITING

Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Liquid Molecular Testing Panel in the Community Setting ("DINOSAur II")

Talk to us

Conditions

Stage III Solid TumorsStage IV Solid Tumors

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive l i q u i d molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.

Official Title

Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Liquid Molecular Testing Panel in the Community Setting. ("DINOSAur II")

Quick Facts

Study Start:2023-02-01
Study Completion:2025-01-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05703243

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients who have given informed consent in accordance with the methods and procedures of this study
  2. * Diagnosis of cancer (stage 3 and stage 4; solid tumors only) requiring medical care
  3. * Patients who have not received treatment related to his/her cancer
  4. * Patients who are willing to sign a release of medical records to the research team
  5. * Male and female patients ≥18 years of age
  6. * Patients under oncology care
  7. * Sufficient clinical status for collection of blood sample within usual care
  1. * Patients considered minors in the jurisdiction where the protocol is conducted
  2. * Patients who are prisoners and pregnant women
  3. * Patients who cannot provide consent and did not sign a power of attorney

Contacts and Locations

Study Contact

Mihran H Shirinian, MD
CONTACT
818-543-7574
mshirin@aol.com
Lily Villalobos, MHA
CONTACT
818-409-8009
villall3@ah.org

Principal Investigator

Mihran H Shirinian, MD
PRINCIPAL_INVESTIGATOR
Glendale Adventist Medical Center dba Adventist Health Glendale

Study Locations (Sites)

Adventist Health Glendale
Glendale, California, 91206
United States

Collaborators and Investigators

Sponsor: Glendale Adventist Medical Center d/b/a Adventist Health Glendale

  • Mihran H Shirinian, MD, PRINCIPAL_INVESTIGATOR, Glendale Adventist Medical Center dba Adventist Health Glendale

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-02-01
Study Completion Date2025-01-01

Study Record Updates

Study Start Date2023-02-01
Study Completion Date2025-01-01

Terms related to this study

Additional Relevant MeSH Terms

  • Stage III Solid Tumors
  • Stage IV Solid Tumors